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Purpose/Objective: We conducted a retrospective analysis of 
stage IVA uterine cervical cancer patients from several 
clinical trials of carbon ion radiotherapy (C-ion RT) in 
National Institute of Radiological Sciences. The purpose of 
this study was evaluation of the toxicity and efficacy of C-ion 
RT for FIGO stage IVA uterine cervical cancer. 
Materials and Methods: Between June 1995 and January 
2014, we have conducted 8 clinical trials of C-ion RT for 
locally advanced squamous cell carcinoma or adenocarcinoma 
of the cervix, and 29 patients with FIGO stage IVA uterine 
cervical cancer were identified in 7 clinical trials. Mean age 
was 56 years old (range 31-79 years old). Median tumor size 
was 6.7 cm (range 3.5-11 cm). Patients with rectal invasion 
were excluded from this analysis because these cases were 
ineligible in our clinical trial. Nineteen of 29 patients had 
enlarged lymph nodes in pelvis. Histologically, 20 patients 
had squamous cell carcinoma and 9 had adenocarcinoma. C-
ion RT was performed as a dose-escalation study at the 
beginning, total dose to cervical tumor was 52.8-74.4 gray 
equivalents, and concurrent chemotherapy was combined in 
4 patients. 
Results: The median follow up time was 28.1 months (range 
4.2-213.8 months). The numbers of Grade 2 or higher major 
late complications were 2 patients (6.9%) in the bladder, and 
6 patients (20.7%) in the rectosigmoid colon. Vesicovaginal 
fistula was observed in 6 patients after the treatment. The 3 
years overall survival rates (3yOS) was 46.7%, the 3 years 
local control rates (3yLC) was 64.9%, and the 3 years 
progression free survival rates (3yPFS) was 33.6%. The 3yOS, 
3yOS, and 3yPFS of patients with squamous cell carcinoma 
were 44.9%, 62.2%, and 34.9%, respectively. Those with 
adenocarcinoma were 52.5%, 75.0%, and 23.9%, respectively. 
Conclusions: Although the number of patients in this analysis 
was small, these result suggested that C-ion RT for FIGO 
stage IVA uterine cervical cancer would be an effective 
method.  
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Purpose/Objective: To determine the recommended 
preoperative dose of large-field IMRT chemoradiation along 
with simultaneous integrated boost (SIB) dose escalation on 
the tumor and pelvic nodes in locally advanced cervical 
carcinoma (LACC). 
Materials and Methods: A radiation dose of 40 Gy over four 
weeks, 2 Gy per fraction, was delivered to the tumor and the 
lymphatic drainage (planning target volume, PTV3), which 
encompassed a volume larger than standard (upper field 
border: L3 vertebra), concurrently with chemotherapy 
(cisplatin and 5-fluorouracil). Radiation dose was escalated 
to the pelvic nodes (PTV2) and macroscopic disease (PTV1) 
with a SIB strategy. Three dose levels were planned as shown 
in Table 1 up to a dose of 50/2.5 Gy on PTV1. Patients were 
treated in cohorts of three to six per group using a phase I 
study design. The recommended dose was exceeded if 2 of 6 
patients in a cohort experienced dose-limiting toxicity (DLT). 
 
Results: 19 patients (median age: 46 years; FIGO stage IB2: 
3, IIB: 10, IIIA: 4, IIIB: 2) were enrolled. Median follow-up was 
36 months (9–60 months). The predominant DLTs were 
gastrointestinal . Since two DLTs (grade 3 diarrhoea, n=2), 
were observed in 6 patients at level III, the decision was to 
close the trial and to consider level II as the recommended 
phase II dose. In the post-operative period, 2 (10.5%) patients 
showed grade 3 GU complications. Concerning long term 
toxicity, actuarial 2y GU toxicity (≥ grade 2) free survival was 
83.6%, neither severe GI complications (≥2) nor late skin 
toxicity (≥2) were observed. Planning constraints for normal 
tissues were always respected except in the case of small 
bowel where only 2 patients respected V15<120 cc 
constraint; in the majority of LACC it was largely exceeded 
with a median value of 268.9 cc (range 96-481 cc). Three of 
the four patients with severe GI toxicity did not meet the 
QUANTEC small bowel constraint V15<120 cc. Concerning 
pathologic response 12 (63.1%) complete response or 
microscopic residual disease were recorded. The 2-year local 
control was 89.5% (median LC: not reached), while the 2-year 
disease free survival (DFS) was 82.0% (median DFS: not 
reached). Death of disease was recorded in 2 of 18 patients 
(10.5%) and the 2-year overall survival (OS) was 88.8% 
(median OS: not reached).  
Conclusions: In a series of 19 LACC patients treated by SIB-
IMRT chemoradiation followed by radical surgery, 40 Gy on 
lumboaortic nodes and 45 Gy on pelvic nodes and 
macroscopic disease were the recommended doses. 
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